A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
CompletedPhase 3NCT02797951
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
Study details
- Official title
- A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache
- Conditions
- Episodic Cluster Headache
- Chronic Cluster Headache
- Interventions
- Drug: Galcanezumab
- Sponsor
- Eli Lilly and Company
- Start date
- 2016-07-13
- Primary completion
- 2021-01-21
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom, United States
- Total sites listed
- 40
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Participants who participated in and completed either study CGAL or study CGAM. * Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements. Exclusion Criteria: * Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of Study CGAL or Study CGAM). * Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF) (with the exception of Study CGAL or Study CGAM). * A history of migraine variants that could implicate or could be confused with ischemia. * Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. * A history or presence of other medical illness that indicates a medical problem that would preclude study participation. * Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator. * Women who are pregnant or nursing.
Canadian sites (2)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02797951